

<HTML>
<HEAD>

<link rel="stylesheet" href="/v3.css" type="text/css">










<TITLE>NEJM -- Case 3-2005 - A 14-Year-Old Boy with Recent Slowing of Growth and Delayed Puberty</TITLE>
<meta name="description" content="Case Records of the Massachusetts General Hospital from The New England Journal of Medicine -- Case 3-2005 - A 14-Year-Old Boy with Recent Slowing of Growth and Delayed Puberty">

<meta name="robots" content="nofollow">




<script type="text/javascript" src="/misc/folders.js"></script>
</HEAD>


  

























	




















<!-- start PPT check-->


<!-- end PPT check-->









 
 
  







<body bgcolor="#FFFFFF" link="#FF3300" vlink="#666699" text="#000000" alink="#FF3300">

<!-- BEGIN: Use this section to set page specific variables for the NetTracker Page Tag -->
<script language="JavaScript">
// var NTPT_PGEXTRA = '';
// var NTPT_PGREFTOP = false;
// var NTPT_NOINITIALTAG = false;
</script>
<!-- END: Use this section to set page specific variables for the NetTracker Page Tag -->
<!-- BEGIN: NetTracker Page Tag -->
<!-- Copyright 2004 Sane Solutions, LLC. All rights reserved. -->
<script language="JavaScript" src="/ntpagetag.js"></script>
<noscript>
<img src="/icons/ntpagetag.gif?js=0" height="1" width="1" border="0" hspace="0" vspace="0" alt="">
</noscript>
<!-- END: NetTracker Page Tag -->







<!-- No CheckM8 category -->




<A NAME="top"><!-- null --></A>

	<table width="100%" border="0" cellspacing="0" cellpadding="0" align="center">
	
	
	<tr align="center"> 
	<td bgcolor="#FF3300"><img src="/icons/spacer.gif" width="1" height="3" alt=""></td>
	</tr>
	
	<tr align="center"> 
	<td><a href="/"><img src="/icons/banner/v2_title_large.gif" border="0" alt="The New England Journal of Medicine" width="482" height="95"></a></td>
	</tr>
	
	<tr> 
	<td valign="top" align="center" bgcolor="#E8E8D1"><img src="/icons/spacer.gif" width="100%" height="5" alt=""></td>
	</tr>
	
	<tr> 
	<td valign="top" align="center" bgcolor="#E8E8D1"><font face="arial, helvetica, sans-serif">
<a href="/" class="navBarLinks">HOME</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/search.dtl" class="navBarLinks">SEARCH</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/current.shtml" class="navBarLinks">CURRENT ISSUE</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/contents-by-date.0.shtml" class="navBarLinks">PAST ISSUES</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/collections/" class="navBarLinks">COLLECTIONS</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/help/" class="navBarLinks">HELP</a>
</font></td>
	</tr>
	
	<tr> 
	<td valign="top" align="center" bgcolor="#E8E8D1"><img src="/icons/spacer.gif" width="100%" height="5" alt=""></td>
	</tr>
	
	<tr> 
	<td valign="top" align="center" bgcolor="#FF3300"><img src="/icons/spacer.gif" width="1" height="3" alt=""></td>
	</tr>
	
	<tr> 
	<td><img src="/icons/spacer.gif" width="100%" height="1" alt=""></td>
	</tr>
	
	<tr> 
	<td><font face="arial, helvetica, sans-serif" size="-2"><!-- subline logic: standard default -->







	
	

	





	
	
	
	 

	


	
	




				<FONT SIZE=-2>




				<NOBR><STRONG>Institution: BRANDEIS UNIV</STRONG></NOBR>

				
	   				
					
				
				| <NOBR><A TARGET="_top" HREF="/cgi/login?uri=%2Fcgi%2Fcontent%2Ffull%2F352%2F4%2F393">Sign In as Individual</A></NOBR>
				|
				<NOBR><A TARGET="_top" HREF="mailto:keen@brandeis.edu">Contact Subscription Administrator at Your Institution</A></NOBR>
				
				 | <NOBR><STRONG><A TARGET="_top" HREF="http://www.nejm.org/Institute/faq.asp">FAQ</A></STRONG></NOBR>

				</FONT>
			

 <!-- showauthstring -->
	<!-- INST -->
	<!-- INDV -->
        <!-- SPONSORED -->
	<!-- USER.PFA -->
	<!-- USER.PFABSAIC -->
	<!-- NOT GUEST -->
	

	


</font></td>
	</tr>
	
		
		<tr>
		<td>&nbsp;</td>
		</tr>
	
	
	</table>
	
	
<!-- include file -->
<!-- (do not remove) -->




         
                
        






<CENTER>
<table width="640" border="0" cellspacing="0" cellpadding="0">
	<TR VALIGN="TOP"> 
		<TD> 
			
								
				
				<DIV ALIGN="CENTER">
	<IMG VSPACE="7" SRC="/icons/content/v2_case_rec_head.gif" ALT="Case Records of the Massachusetts General Hospital">
	  
	  
	    <BR><IMG SRC="/icons/content/series/case_weekly_ednames_010604.gif" ALT="Editor's Names">
	  
	

	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	

				
          		<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="640">
				<TR>
					<TD VALIGN="TOP" NOWRAP><A HREF="/cgi/content/short/352/4/392?query=prevarrow"><IMG ALT="Previous" WIDTH="9" HEIGHT="8" HSPACE="4" BORDER="0" SRC="/icons/v2_toc_arrowprev.gif"><FONT SIZE="-1" FACE="arial,helvetica">Previous</FONT></A></TD>
          			<TD ALIGN="CENTER" VALIGN="TOP"><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0">
						<TH ALIGN="RIGHT" VALIGN="TOP" NOWRAP>Volume 352:393-403</TH>
						<TD NOWRAP><IMG ALT="" WIDTH="30" HEIGHT="30" SRC="/icons/spacer.gif"></TD>
						<TH VALIGN="TOP" NOWRAP><A HREF="/content/vol352/issue4/index.shtml"><FONT COLOR="#000000">January 27, 2005</FONT></A></TH>
						<TD NOWRAP><IMG ALT="" WIDTH="30" HEIGHT="30" SRC="/icons/spacer.gif"></TD>
						<TH ALIGN="LEFT" VALIGN="TOP" NOWRAP>Number 4</TH>
					</TR></TABLE></TD>
					<TD VALIGN="TOP" ALIGN="RIGHT" NOWRAP><A HREF="/cgi/content/short/352/4/405?query=nextarrow"><FONT SIZE="-1" FACE="arial,helvetica">Next</FONT><IMG ALT="Next" WIDTH="9" HEIGHT="8" HSPACE="4" BORDER="0" SRC="/icons/v2_toc_arrownext.gif"></A></TD>
          		</TR>
				</TABLE>
				
          		</DIV>
      			
      		

      </TD>
    </TR>
</TABLE>
</CENTER>
<P>





<div align="center"><b><FONT SIZE="+2" face="Arial, Helvetica, sans-serif">Case 3-2005 &#151; A 14-Year-Old Boy with Recent Slowing of Growth and Delayed Puberty</FONT></B><BR></div>


	
	<CENTER><FONT SIZE="+1"><I>
	
	
			Esther J. Israel, M.D., Lynne L. Levitsky, M.D., Sudha A. Anupindi, M.D., and Martha B. Pitman, M.D.
		
	</I></FONT></CENTER>







<P>

 



 
		                    



 
	 

<table border="0" cellpadding="0" cellspacing="0" width="200" ALIGN="RIGHT">
<tr>
<td width="20">&nbsp;</td>
<TD BGCOLOR="336699">

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="1">

	<TR VALIGN="top">
		<td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
			<img src="/icons/v3_this_article.gif" alt="This Article" width="73" height="8" BORDER="0"><BR>
			<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
	</tr><tr>
		<td> 
                <table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
		<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
		
		
		
		

		
		 

		
		<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b>
			
			
			
				
						
						<A class="contentboxLinks" HREF="/cgi/reprint/352/4/393.pdf">PDF</A></b></font></td></tr>
		
		<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/ac_external_ref?link_type=pda_mms&doi=10.1056%2FNEJMcpc049032">PDA Full Text</A></b></font></td></tr>
		
		
		

		

		

		 
		
		



	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	</table>
        </td>
        </tr>









	<tr> 
	<td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
	<img src="/icons/v3_tools_service.gif" alt="Tools and Services" width="103" height="9" align="absmiddle"><BR>
	<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
	</tr>
	<tr> 
	<td> 
	<table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	
		
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/folders?action=addtofolder&wherefrom=JOURNALS&wrapped_id=nejm;352/4/393">Add to Personal Archive</A></b></font></td></tr>
	
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/citmgr?gca=nejm;352/4/393">Add to Citation Manager</A></b></font></td></tr>
	
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/mailafriend?url=http://content.nejm.org/cgi/content/short/352/4/393&title=Case+3-2005+-+A+14-Year-Old+Boy+with+Recent+Slowing+of+Growth+and+Delayed+Puberty"><b>Notify a Friend</b></a></b></font></td></tr>

	
        <tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=nejm;352/4/393&return_type=article&return_url=%2Fcgi%2Fcontent%2Ffull%2F352%2F4%2F393">E-mail When Cited</A></b></font></td></tr>

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/ac_external_ref?link_type=letters_mms&doi=10.1056%2FNEJMcpc049032">E-mail When Letters Appear</A></b></font></td></tr>
	
	
	
	

	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	</table>
        </td>
        </tr>



        <tr>
        <td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
	<img src="/icons/v3_more_information.gif" alt="More Information" width="116" height="8" align="absmiddle"><BR>
	<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
        </tr>
        <tr>
        <td>
        <table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
        

	

	

	

	

	

	

	

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/search?qbe=nejm;352/4/393&journalcode=nejm&minscore=5000">Find Similar Articles</A></b></font></td></tr>

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/external_ref?access_num=15673806&link_type=PUBMED" onClick="ISIwin('ISI')" TARGET="ISI">PubMed Citation</A></b></font></td></tr>

<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
</table>
</td>
</tr>

        
        
</table>
</table>	 <!-- end of outer content box1 -->
</TABLE>	 <!-- end of outer content box2 -->










 





	
	
	
	
	
	
	
	
	
		


<!-- <CENTER><H2><FONT FACE="arial, helvetica">
Case 3-2005
</FONT></H2> </CENTER> -->
<!-- <H3>
A 14-Year-Old Boy with Recent Slowing of Growth and Delayed Puberty
</H3> -->


<!--<CENTER><I>
</NOBR><NOBR>Esther J. Israel, M.D.</NOBR>, 
<NOBR>Lynne L. Levitsky, M.D.</NOBR>, 
<NOBR>Sudha A. Anupindi, M.D.</NOBR> and 
<NOBR>Martha B. Pitman, M.D.</NOBR>
</I></CENTER><P>
-->


<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Presentation of Case</STRONG></FONT><P>

A 14-year-old boy was evaluated in the pediatric endocrinology<SUP> </SUP>clinic because of decreased endurance, slow growth, and delayed<SUP> </SUP>onset of puberty.<SUP> </SUP><P>

Ten weeks before his presentation at the clinic, he saw his<SUP> </SUP>pediatrician because of concern regarding his short stature,<SUP> </SUP>lack of energy, and youthful appearance relative to his male<SUP> </SUP>peers. The patient had been well until approximately four years<SUP> </SUP>previously, when he had had an episode of diarrhea that persisted<SUP> </SUP>for 19 days and was associated with a weight loss of approximately<SUP> </SUP>1.5 kg, without fever or abdominal pain. The patient's father<SUP> </SUP>also had diarrhea during some of that time. The boy was treated<SUP> </SUP>with metronidazole for a presumptive diagnosis of giardia, and<SUP> </SUP>his stools became solid. The results of stool examination for<SUP> </SUP>the presence of ova and parasites, and of routine bacterial<SUP> </SUP>cultures for <I>Clostridium difficile,</I> rotavirus, and yersinia<SUP> </SUP>were negative. The boy returned to his usual state of health,<SUP> </SUP>but his mother noted that after the illness he seemed to have<SUP> </SUP>dark circles under his eyes, had poor skin color, and reported<SUP> </SUP>intermittent bouts of foul-smelling flatulence. In the year<SUP> </SUP>before this evaluation, he began to have behavior problems and<SUP> </SUP>increasing difficulty focusing on schoolwork. He was referred<SUP> </SUP>to the pediatric endocrinology clinic of this hospital.<SUP> </SUP><P>

The patient had been born by cesarean section, which had been<SUP> </SUP>indicated for cephalopelvic disproportion, at a gestational<SUP> </SUP>age of 39 weeks, and weighed 3.5 kg at birth. He had no allergies,<SUP> </SUP>was taking no medications when he came to the clinic, and had<SUP> </SUP>had the usual childhood immunizations. He was a student in the<SUP> </SUP>eighth grade. In the interval since his visit to the pediatrician,<SUP> </SUP>he had begun to notice underarm odor and to use deodorant, and<SUP> </SUP>pubic hair had developed.<SUP> </SUP><P>

The mother's height was 173 cm and father's 183 cm. Other female<SUP> </SUP>relatives ranged in height from 165 to 173 cm, and male relatives<SUP> </SUP>from 183 to 191 cm. A female cousin had had a delayed puberty<SUP> </SUP>for which she had been treated with hormone therapy; several<SUP> </SUP>second-degree female relatives had thyroid disease. The maternal<SUP> </SUP>grandfather had a history of rickets in childhood and had been<SUP> </SUP>thin all his life; at 75 years of age, he was told that he could<SUP> </SUP>not absorb vitamin B<SUB>12</SUB> and had required B<SUB>12</SUB> shots thereafter.<SUP> </SUP>He died at 78 years of age of diffuse large-B-cell lymphoma.<SUP> </SUP><P>

On physical examination, the boy's height was 159 cm and the<SUP> </SUP>weight was 42.9 kg (<A HREF="#F1">Figure 1</A>). The blood pressure was 112/74<SUP> </SUP>mm Hg and the pulse 68 beats per minute. The head circumference<SUP> </SUP>was 55 cm and the arm span 159 cm, and he had an upper-to-lower<SUP> </SUP>body-segment ratio of 0.8. He had a slightly high-arched palate,<SUP> </SUP>and shotty lymphadenopathy was present at the angle of the mandible<SUP> </SUP>bilaterally. His thyroid was palpable and not enlarged. His<SUP> </SUP>head, eyes, ears, nose, throat, lungs, heart, abdomen, and extremities<SUP> </SUP>all appeared normal; the neurologic examination showed no abnormalities.<SUP> </SUP>The estimated testicular volume was 5 ml on the left and 4 ml<SUP> </SUP>on the right. His pubic hair, as assessed by the Tanner classification<SUP> </SUP>of sexual development, was stage 2 and his axillary hair was<SUP> </SUP>stage 1 (the range is from 1, for preadolescent characteristics,<SUP> </SUP>to 5, for adult characteristics).<SUP> </SUP><P>

<A NAME="F1"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/352/4/393/F1"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=125 HEIGHT=128 SRC="/content/vol352/issue4/images/small/14f1.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (77K):<BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/F1">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/F1"
    onClick="startTarget('F1', 578, 640); this.href='/cgi/content-nw/full/352/4/393/F1'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F1">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 1.</B> Growth Chart.<P>

The black Xs indicate growth points before and at the time of the patient's initial evaluation. The rate of weight gain began to slow at approximately 10 years of age, and the rate of height increase began to slow one year later. The red Xs indicate growth points after treatment.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


A radiograph of the left hand obtained at a chronologic age<SUP> </SUP>of 14 years 2 months showed a bone age of 12 years 6 months<SUP> </SUP>(<A HREF="#F2">Figure 2</A>). Results of laboratory tests are shown in <A HREF="#T1">Table 1</A>.<SUP> </SUP>A diagnostic procedure was performed.<SUP> </SUP><P>

<A NAME="F2"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/352/4/393/F2"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=52 HEIGHT=128 SRC="/content/vol352/issue4/images/small/14f2.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (45K):<BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/F2">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/F2"
    onClick="startTarget('F2', 329, 640); this.href='/cgi/content-nw/full/352/4/393/F2'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F2">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 2.</B> Radiographs of the Patient's Left Hand at a Chronologic Age of 14 Years 2 Months (Panel A) and the Hand of a Normal 14-Year-Old (Panel B).<P>

In the patient's hand, unlike the normal hand, the sesamoid bone of the thumb has not developed, and the epiphyses (arrows) of the phalanges are shorter and not cupped. According to the bone-age standards of Greulich and Pyle,<A HREF="#R1"><SUP>1</SUP></A> the patient's bone age is between 12 years and 12 years 6 months, indicating a slight delay in growth.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


<A NAME="T1"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<STRONG>View this table:</STRONG><BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/T1">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/T1"
    onClick="startTarget('T1', 590, 1206); this.href='/cgi/content-nw/full/352/4/393/T1'"
 	onMouseOver="window.status='View table in a separate window'; return true"
 	TARGET="T1">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Table 1.</B> Laboratory-Test Results.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Differential Diagnosis</STRONG></FONT><P>

<I>Dr. Lynne L. Levitsky:</I> May we review the bone-age radiograph?<SUP> </SUP><P>

<I>Dr. Sudha A. Anupindi:</I> On the basis of the standards compiled<SUP> </SUP>by Greulich and Pyle,<A HREF="#R1"><SUP>1</SUP></A> the bone age of a child is calculated<SUP> </SUP>on a radiograph of the left hand (<A HREF="#F2">Figure 2A</A>). The configuration,<SUP> </SUP>development, and length of the epiphyses of the phalanges of<SUP> </SUP>the fingers and carpal bones of a patient are compared with<SUP> </SUP>those of the established standard bone ages (<A HREF="#F2">Figure 2B</A>). The<SUP> </SUP>presence of the sesamoid bone of the thumb is a critical feature;<SUP> </SUP>the sesamoid appears in girls by age 11 and in boys by age 13.<SUP> </SUP>The bone age should fall within 2 SD of the chronologic age.<SUP> </SUP>If the bone age is more than 2 SD below the chronologic age,<SUP> </SUP>the child's bone growth is delayed, and if the bone age is more<SUP> </SUP>than 2 SD greater than the chronologic age, the child is advanced<SUP> </SUP>in bone age. At a chronologic age of 14 years 2 months, the<SUP> </SUP>hand radiograph appeared to have a bone age between 12 years<SUP> </SUP>and 12 years 6 months (SD, 10.7 months), which would mean that<SUP> </SUP>the child's bone growth was slightly delayed (at the lower limit<SUP> </SUP>of the normal range).<SUP> </SUP><P>

<I>Dr. Levitsky:</I> This young man presented with modest attenuation<SUP> </SUP>in weight gain and longitudinal growth. He was within the normal<SUP> </SUP>percentiles, and his growth rate was within the normal range<SUP> </SUP>for a boy with delayed puberty in the phase of prepubertal growth<SUP> </SUP>attenuation (the third percentile for growth rate during prepubertal<SUP> </SUP>growth attenuation is about 3.5 cm per year).<A HREF="#R2"><SUP>2</SUP></A> By the time I<SUP> </SUP>saw him, it appeared, looking at his growth plot on a standard<SUP> </SUP>cross-sectional growth curve, that he was beginning to grow<SUP> </SUP>normally, although his height was in a lower percentile than<SUP> </SUP>it had been previously (<A HREF="#F1">Figure 1</A>). Diminished weight gain predated<SUP> </SUP>the height deceleration, but recent weight gain also appeared<SUP> </SUP>to be normal, between the 10th and the 25th percentile over<SUP> </SUP>the course of the year before his first visit to the clinic.<SUP> </SUP><P>

The differential diagnosis of growth attenuation or short stature<SUP> </SUP>is reviewed in <A HREF="#T2">Table 2</A>. In general, children with endocrine<SUP> </SUP>disorders have attenuated linear growth, rather than attenuated<SUP> </SUP>weight gain. In contrast, children with underlying chronic illness<SUP> </SUP>have attenuation in weight gain before linear growth slows.<A HREF="#R3"><SUP>3</SUP></A><SUP> </SUP>The history and physical examination of this patient were helpful<SUP> </SUP>in eliminating many of the categories of growth disorders delineated<SUP> </SUP>in <A HREF="#T3">Table 3</A>. The patient had no prenatal problems, no family<SUP> </SUP>history of short stature, and no history of medication that<SUP> </SUP>could interfere with growth, and he had normal body proportions<SUP> </SUP>and appearance, making a genetic abnormality of bone or cartilage<SUP> </SUP>growth unlikely. A second-degree female relative did have delayed<SUP> </SUP>puberty.<SUP> </SUP><P>

<A NAME="T2"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<STRONG>View this table:</STRONG><BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/T2">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/T2"
    onClick="startTarget('T2', 591, 591); this.href='/cgi/content-nw/full/352/4/393/T2'"
 	onMouseOver="window.status='View table in a separate window'; return true"
 	TARGET="T2">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Table 2.</B> Differential Diagnosis of Growth Attenuation or Short Stature.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


<A NAME="T3"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<STRONG>View this table:</STRONG><BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/T3">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/T3"
    onClick="startTarget('T3', 730, 799); this.href='/cgi/content-nw/full/352/4/393/T3'"
 	onMouseOver="window.status='View table in a separate window'; return true"
 	TARGET="T3">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Table 3.</B> Laboratory Evaluation of Short Stature and Growth Attenuation.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


I thought that either the patient was a normal boy who was delayed<SUP> </SUP>in his maturation or that he had a chronic illness. I, therefore,<SUP> </SUP>screened for an underlying chronic illness, and I did not obtain<SUP> </SUP>most of the studies listed in <A HREF="#T3">Table 3</A>. He had mild anemia, which<SUP> </SUP>is unusual in a boy his age, and therefore when the IgA antiendomysial<SUP> </SUP>antibody study returned strongly positive at a titer of 1:1280,<SUP> </SUP>suggesting celiac disease, I was not entirely surprised.<SUP> </SUP><P>

The incidence of celiac disease in children with short stature<SUP> </SUP>ranges from 2 to 8 percent,<A HREF="#R4"><SUP>4</SUP></A><SUP>,</SUP><A HREF="#R5"><SUP>5</SUP></A> depending on the selection criteria,<SUP> </SUP>the age of the subjects, and the definition of short stature.<SUP> </SUP>Nonetheless, celiac disease must be considered in the differential<SUP> </SUP>diagnosis of any child with growth attenuation, particularly<SUP> </SUP>if there is also attenuation in weight. The relationship of<SUP> </SUP>this chronic gastrointestinal disorder to growth attenuation<SUP> </SUP>is not clear.<SUP> </SUP><P>

Undernutrition is not the complete answer. Severe growth attenuation<SUP> </SUP>develops in many children with celiac disease who are minimally<SUP> </SUP>underweight, and many normal, thin children grow well. Children<SUP> </SUP>with severe undernutrition may have low levels of peripheral<SUP> </SUP>insulin-like growth factor I (IGF-I). Circulating IGF-I, produced<SUP> </SUP>largely by the liver, is both growth hormone&#150;dependent<SUP> </SUP>and insulin-dependent. Low levels of circulating IGF-I may be<SUP> </SUP>a cause of growth attenuation.<A HREF="#R6"><SUP>6</SUP></A> An increase in the production<SUP> </SUP>of inflammatory cytokines in the gut may interfere with growth-factor<SUP> </SUP>production or action at the cellular level and may play a role<SUP> </SUP>in growth attenuation.<A HREF="#R7"><SUP>7</SUP></A> Other gastrointestinal disorders, such<SUP> </SUP>as inflammatory bowel disease, may be associated with growth<SUP> </SUP>attenuation before the onset of substantial weight loss or subjective<SUP> </SUP>bowel symptoms.<SUP> </SUP><P>

<I>Dr. Esther J. Israel:</I> This young man was referred to the pediatric<SUP> </SUP>gastroenterology and nutrition unit to confirm that he had celiac<SUP> </SUP>disease &#151; an immune-mediated enteropathy that is triggered<SUP> </SUP>in genetically susceptible persons by the ingestion of gluten<SUP> </SUP>and results in malabsorption. Since the classic presentation<SUP> </SUP>of celiac disease, with diarrhea, abdominal distention, and<SUP> </SUP>poor weight gain, typically occurs between the ages of six months<SUP> </SUP>and two years, after the introduction of cereals into the diet,<SUP> </SUP>it was not initially considered by this patient's pediatrician.<SUP> </SUP>However, in the past 15 years, new diagnostic tools &#151;<SUP> </SUP>which can test for antigliadin, antiendomysial, and anti&#150;tissue<SUP> </SUP>transglutaminase antibodies &#151; have led to the recognition<SUP> </SUP>of the disease in increasing numbers of patients without the<SUP> </SUP>classic presentation, as well as in the general population.<A HREF="#R8"><SUP>8</SUP></A><SUP> </SUP>Screening has resulted in a marked increase in the estimated<SUP> </SUP>prevalence of the disease worldwide: in the United States the<SUP> </SUP>prevalence, once estimated to be as low as 1 of every 10,000<SUP> </SUP>people, is now estimated to be 1 of every 111 people.<A HREF="#R9"><SUP>9</SUP></A><SUP> </SUP><P>

<STRONG>Clinical Spectrum of Celiac Disease</STRONG><P>

Nonclassic manifestations of celiac disease can be divided into<SUP> </SUP>two categories: those that appear to be due to malabsorption,<SUP> </SUP>and those due to associated autoimmune diseases. Presentation<SUP> </SUP>with symptoms related to malabsorption is seen in all age groups.<SUP> </SUP>Younger patients may present with recurrent abdominal pain,<SUP> </SUP>anemia, or, as demonstrated in this patient, attenuated growth<SUP> </SUP>and delayed puberty. Almost 30 percent of children with subclinical<SUP> </SUP>celiac disease have short stature as their leading symptom.<A HREF="#R10"><SUP>10</SUP></A><SUP> </SUP>Iron-deficiency anemia, which this boy also had, is the most<SUP> </SUP>common clinical symptom in adults; whereas adults may have episodic<SUP> </SUP>or nocturnal diarrhea, many do not.<A HREF="#R11"><SUP>11</SUP></A> Abdominal discomfort and<SUP> </SUP>bloating are common and often lead to the initial diagnosis<SUP> </SUP>of irritable bowel syndrome.<A HREF="#R8"><SUP>8</SUP></A><SUP> </SUP><P>

Other manifestations of malabsorption that should prompt evaluation<SUP> </SUP>for celiac disease include macrocytic anemia due to the malabsorption<SUP> </SUP>of folate and, less commonly, vitamin B<SUB>12</SUB>; coagulopathy due<SUP> </SUP>to vitamin K deficiency; and hypocalcemia, osteopenia, and bone<SUP> </SUP>fractures as a result of poor absorption of vitamin D. A recent<SUP> </SUP>report<A HREF="#R12"><SUP>12</SUP></A>  described a man with celiac disease who presented<SUP> </SUP>with low back and leg pain due to vitamin D deficiency and osteomalacia.<SUP> </SUP><P>

Manifestations that reflect the autoimmune nature of celiac<SUP> </SUP>disease include dermatitis herpetiformis, arthritis, diabetes,<SUP> </SUP>and hepatitis, none of which this patient had. Clinically silent<SUP> </SUP>celiac disease is found in up to 30 percent of children with<SUP> </SUP>type 1 diabetes mellitus.<A HREF="#R13"><SUP>13</SUP></A> The prevalence of autoimmune disorders<SUP> </SUP>is higher than usual in celiac disease<A HREF="#R14"><SUP>14</SUP></A> and is proportional<SUP> </SUP>to the duration of exposure to gluten,<A HREF="#R15"><SUP>15</SUP></A> suggesting that the<SUP> </SUP>occurrence of such disorders could be prevented by the early<SUP> </SUP>detection of celiac disease and the elimination of gluten from<SUP> </SUP>the patients' diets.<A HREF="#R8"><SUP>8</SUP></A> Thus, primary care physicians need to<SUP> </SUP>have a high index of suspicion for celiac disease in patients<SUP> </SUP>with autoimmune disorders.<SUP> </SUP><P>

<STRONG>Serologic Testing for Celiac Disease</STRONG><P>

Antigliadin antibodies are sensitive indicators of the diagnosis<SUP> </SUP>of celiac disease, but they may also be present in persons without<SUP> </SUP>celiac disease. They are, however, excellent tools for measuring<SUP> </SUP>a patient's adherence to a gluten-free diet.<A HREF="#R16"><SUP>16</SUP></A> An immunofluorescence<SUP> </SUP>test for the antiendomysial antibody, directed against a connective-tissue<SUP> </SUP>protein in the gastrointestinal tract, was found to have a sensitivity<SUP> </SUP>and specificity for celiac disease in the range of 95 to 97<SUP> </SUP>percent. More recently, tissue transglutaminase was discovered<SUP> </SUP>to be the antigen for the endomysial antibody, and an enzyme-linked<SUP> </SUP>immunosorbent assay (ELISA) was developed, which is more reproducible<SUP> </SUP>but slightly less specific than the immunofluorescence test.<A HREF="#R17"><SUP>17</SUP></A><SUP> </SUP>Most commercial laboratories use the ELISA, so that even if<SUP> </SUP>antiendomysial-antibody testing is requested, it is usually<SUP> </SUP>a tissue transglutaminase antibody that is measured.<SUP> </SUP><P>

<STRONG>Diagnostic Criteria for Celiac Disease</STRONG><P>

Given the positive antiendomysial-antibody test in this patient,<SUP> </SUP>what is the next step in confirming the diagnosis? The advent<SUP> </SUP>of serologic testing has changed the algorithm for the diagnosis<SUP> </SUP>of celiac disease. Previously,<A HREF="#R18"><SUP>18</SUP></A> it was a three-step process:<SUP> </SUP>a small-bowel biopsy that showed evidence of mucosal injury<SUP> </SUP>in a patient with gastrointestinal symptoms compatible with<SUP> </SUP>celiac disease, resolution of symptoms and pathological abnormalities<SUP> </SUP>while the patient followed a gluten-free diet, and a gluten<SUP> </SUP>challenge with repeated small-bowel biopsy that showed recurrence<SUP> </SUP>of the disease. Revised criteria, established in 1990,<A HREF="#R19"><SUP>19</SUP></A> still<SUP> </SUP>call for a small-bowel biopsy to confirm the diagnosis of celiac<SUP> </SUP>disease, if serologic studies suggest the disease. The serologic<SUP> </SUP>studies are repeated six months to a year after the patient<SUP> </SUP>has adopted a gluten-free diet. The resolution of symptoms and<SUP> </SUP>disappearance of antibodies confirm the diagnosis of celiac<SUP> </SUP>disease, and a gluten challenge is not needed.<SUP> </SUP><P>

For diagnostic testing of various groups for celiac disease,<SUP> </SUP>I would suggest the algorithm proposed in <A HREF="#F3">Figure 3</A>. Patients<SUP> </SUP>in any of the categories shown should have a tissue transglutaminase<SUP> </SUP>antibody test and an assessment of their total IgA levels. If<SUP> </SUP>the patient is not IgA-deficient and the test for tissue transglutaminase<SUP> </SUP>antibody is negative, celiac disease is unlikely and a biopsy<SUP> </SUP>is not needed. If the antibody test is positive, biopsy of the<SUP> </SUP>small bowel should be performed; if changes associated with<SUP> </SUP>celiac disease are present, the diagnosis is established. If<SUP> </SUP>results of the small-bowel biopsy are not diagnostic, the patient<SUP> </SUP>should be monitored with sequential measurements of bone density,<SUP> </SUP>and an assessment of vitamin status and a repeated biopsy should<SUP> </SUP>be considered. HLA typing for the DQ2 and DQ8 haplotypes can<SUP> </SUP>be performed; however, since these haplotypes are present in<SUP> </SUP>30 percent of the population, their presence is not specific.<SUP> </SUP><P>

<A NAME="F3"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/352/4/393/F3"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=128 HEIGHT=100 SRC="/content/vol352/issue4/images/small/14f3.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (15K):<BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/F3">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/F3"
    onClick="startTarget('F3', 590, 545); this.href='/cgi/content-nw/full/352/4/393/F3'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F3">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 3.</B> Algorithm for the Diagnosis of Celiac Disease in Different Populations.<P>

Patients with classic symptoms of celiac disease, those with atypical symptoms, patients from at-risk populations, and those who have undergone small-bowel biopsy for other reasons that suggest possible celiac disease should have a test for tissue transglutaminase (TTG) antibodies and measurement of total IgA. If the patient is not IgA-deficient and the TTG-antibody test is negative, celiac disease is unlikely. If the TTG-antibody test is positive, a biopsy of the small bowel should be performed; if changes associated with celiac disease are present, the diagnosis is established. If the small-bowel biopsy is not diagnostic, the patient should be monitored and a repeated biopsy considered. HLA typing for DQ2 and DQ8 haplotypes can be performed; if the assay is negative, the patient does not have celiac disease.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


In this patient, the combination of growth attenuation and a<SUP> </SUP>positive test for antiendomysial antibodies was strongly indicative<SUP> </SUP>of celiac disease. I performed upper gastrointestinal endoscopy<SUP> </SUP>to obtain a biopsy specimen of his small intestine. The esophagus<SUP> </SUP>and stomach appeared normal; there was subtle flattening of<SUP> </SUP>the mucosal folds in the duodenum.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Dr. Esther J. Israel's Diagnosis</STRONG></FONT><P>

Celiac disease.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Pathological Discussion</STRONG></FONT><P>

<I>Dr. Martha B. Pitman:</I> We received six biopsy specimens from<SUP> </SUP>the duodenum, two from the gastric antrum, and two from the<SUP> </SUP>esophagus. The esophagus and antrum were normal. The duodenal<SUP> </SUP>mucosa was architecturally distorted, with partial-to-total<SUP> </SUP>villous atrophy, crypt hyperplasia, and an increase in the number<SUP> </SUP>of intraepithelial lymphocytes. All of these morphologic changes<SUP> </SUP>are consistent with celiac disease in a patient with antiendomysial<SUP> </SUP>or anti&#150;tissue transglutaminase antibodies (<A HREF="#F4">Figure 4</A>).<SUP> </SUP><P>

<A NAME="F4"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/352/4/393/F4"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=128 HEIGHT=98 SRC="/content/vol352/issue4/images/small/14f4.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (99K):<BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/F4">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/F4"
    onClick="startTarget('F4', 590, 537); this.href='/cgi/content-nw/full/352/4/393/F4'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F4">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 4.</B> Duodenal-Biopsy Specimen (Hematoxylin and Eosin).<P>

In Panel A, the duodenal mucosa shows villi that are markedly atrophic to absent, with hyperplastic crypts and extensive intraepithelial lymphocytosis &#151; findings that are typical of the destructive stage of celiac disease (Marsh type 3). Panel B shows a higher-power version of the same image, in which damaged cuboidal enterocytes, mitotic figures in the hyperplastic crypts (arrow), and many intraepithelial lymphocytes (arrowheads) are evident. An image of normal duodenal mucosa from another patient (Panel C) shows tall, thin villi, with no crypt hyperplasia, a normal crypt-to-villus ratio of 1:3, and only a few intraepithelial lymphocytes. Panel D shows a higher-power image of the normal mucosa, in which tall columnar enterocytes and a few widely scattered intraepithelial lymphocytes (arrow) are evident.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


It is recommended that a minimum of four biopsy specimens of<SUP> </SUP>the duodenum be obtained for evaluation of patients in whom<SUP> </SUP>celiac disease is suspected, to ensure that at least some tissue<SUP> </SUP>fragments will have the proper orientation, and because villous<SUP> </SUP>injury can be patchy. Many conditions can cause villous injury<SUP> </SUP>and even produce a flat mucosa<A HREF="#R20"><SUP>20</SUP></A> (<A HREF="#T4">Table 4</A>), but few have the<SUP> </SUP>three elements of villous injury, crypt hyperplasia, and intraepithelial<SUP> </SUP>lymphocytosis, and most have clinical manifestations that differ<SUP> </SUP>from those of celiac disease. The diagnosis of celiac disease<SUP> </SUP>should always be included in the differential diagnosis when<SUP> </SUP>a duodenal biopsy shows intraepithelial lymphocytosis, with<SUP> </SUP>or without villous injury. This is important, since it may be<SUP> </SUP>the first time the diagnosis is considered, especially in a<SUP> </SUP>patient with nonspecific gastrointestinal symptoms or none.<SUP> </SUP><P>

<A NAME="T4"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<STRONG>View this table:</STRONG><BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/T4">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/T4"
    onClick="startTarget('T4', 593, 717); this.href='/cgi/content-nw/full/352/4/393/T4'"
 	onMouseOver="window.status='View table in a separate window'; return true"
 	TARGET="T4">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Table 4.</B> Histologic Differential Diagnosis of Celiac Disease.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


The sequential histologic changes that occur in celiac disease<SUP> </SUP>have been classified by Marsh into five stages<A HREF="#R21"><SUP>21</SUP></A> (<A HREF="#T5">Table 5</A>).<SUP> </SUP>This patient's biopsy specimen was classified as Marsh type<SUP> </SUP>3, which is the most commonly observed lesion in celiac disease<SUP> </SUP>and which, in combination with elevated antibody titers, is<SUP> </SUP>considered diagnostic of celiac disease. All stages include<SUP> </SUP>an increase in the number of intraepithelial lymphocytes. Although<SUP> </SUP>Marsh states that as many as 40 intraepithelial lymphocytes<SUP> </SUP>per 100 enterocytes can be normal, other studies have shown<SUP> </SUP>that the range of the number of intraepithelial lymphocytes<SUP> </SUP>in duodenal-biopsy specimens from patients with confirmed celiac<SUP> </SUP>disease is much broader,<A HREF="#R22"><SUP>22</SUP></A><SUP>,</SUP><A HREF="#R23"><SUP>23</SUP></A><SUP>,</SUP><A HREF="#R24"><SUP>24</SUP></A><SUP>,</SUP><A HREF="#R25"><SUP>25</SUP></A> and it can be as low as<SUP> </SUP>13 per 100 enterocytes. Thus, celiac disease may be underdiagnosed<SUP> </SUP>by pathologists who adhere strictly to the higher threshold,<SUP> </SUP>especially in evaluating biopsy specimens with only minor or<SUP> </SUP>focal villous injury.<SUP> </SUP><P>

<A NAME="T5"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<STRONG>View this table:</STRONG><BR>
<NOBR><A HREF="/cgi/content/full/352/4/393/T5">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/352/4/393/T5"
    onClick="startTarget('T5', 950, 474); this.href='/cgi/content-nw/full/352/4/393/T5'"
 	onMouseOver="window.status='View table in a separate window'; return true"
 	TARGET="T5">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Table 5.</B> The Marsh Classification of Mucosal Injury in Celiac Disease.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


The pathophysiology of mucosal injury in celiac disease has<SUP> </SUP>been partially elucidated. The immune reaction to gliadin occurs<SUP> </SUP>only in persons who have the HLA haplotype HLA-DQ2 (90 to 95<SUP> </SUP>percent of patients with celiac disease) or HLA-DQ8 (5 to 10<SUP> </SUP>percent), both of which are major histocompatibility complex<SUP> </SUP>proteins that have a particular affinity for gliadin.<A HREF="#R26"><SUP>26</SUP></A><SUP>,</SUP><A HREF="#R27"><SUP>27</SUP></A><SUP>,</SUP><A HREF="#R28"><SUP>28</SUP></A><SUP>,</SUP><A HREF="#R29"><SUP>29</SUP></A><SUP> </SUP>The immunogenic peptide is a 33-amino-acid peptide of alpha-gliadin<SUP> </SUP>that is produced during normal gastrointestinal digestion and<SUP> </SUP>that is resistant to digestion by all gastric, pancreatic, and<SUP> </SUP>intestinal brush-border membrane proteases.<A HREF="#R29"><SUP>29</SUP></A><SUP>,</SUP><A HREF="#R30"><SUP>30</SUP></A> This peptide<SUP> </SUP>can bind directly to the HLA class II molecules on the surface<SUP> </SUP>of enterocytes.<A HREF="#R30"><SUP>30</SUP></A> Tissue transglutaminase, a ubiquitous intracellular<SUP> </SUP>enzyme, deaminates the peptide, thereby increasing its affinity<SUP> </SUP>for the binding site of the HLA molecule.<A HREF="#R31"><SUP>31</SUP></A><SUP>,</SUP><A HREF="#R32"><SUP>32</SUP></A> The tightly bound<SUP> </SUP>antigen efficiently stimulates CD4+ helper T cells in the lamina<SUP> </SUP>propria; these, in turn, stimulate CD8+ cytotoxic T cells,<A HREF="#R25"><SUP>25</SUP></A><SUP>,</SUP><A HREF="#R33"><SUP>33</SUP></A><SUP> </SUP>which infiltrate the epithelium as intraepithelial lymphocytes<SUP> </SUP>and generate cytokines that contribute to the damage to the<SUP> </SUP>villi.<A HREF="#R33"><SUP>33</SUP></A><SUP>,</SUP><A HREF="#R34"><SUP>34</SUP></A> B cells produce antibodies against gliadin and tissue<SUP> </SUP>transglutaminase, which are the antibodies used in screening<SUP> </SUP>for celiac disease, but it is not clear that these antibodies<SUP> </SUP>play a role in the tissue injury.<SUP> </SUP><P>

The 33-amino-acid peptide may also cross the intestinal barrier<SUP> </SUP>through either a transcellular route<A HREF="#R29"><SUP>29</SUP></A><SUP>,</SUP><A HREF="#R35"><SUP>35</SUP></A> or a paracellular<SUP> </SUP>route. The integrity of the intercellular junctions that control<SUP> </SUP>intestinal permeability is regulated, at least in part, by a<SUP> </SUP>molecule called zonulin<A HREF="#R36"><SUP>36</SUP></A><SUP>,</SUP><A HREF="#R37"><SUP>37</SUP></A><SUP>,</SUP><A HREF="#R38"><SUP>38</SUP></A>; this molecule is up-regulated<SUP> </SUP>in patients with celiac disease, increasing the permeability<SUP> </SUP>of the epithelial barrier.<SUP> </SUP><P>

The cycle of injury is perpetuated only in the presence of the<SUP> </SUP>antigen, so a lifelong gluten-free diet is effective treatment.<SUP> </SUP>Digestion of the toxic 33-amino-acid peptide by bacterial endopeptidase<SUP> </SUP>has been demonstrated in vitro and in vivo,<A HREF="#R39"><SUP>39</SUP></A> and this finding<SUP> </SUP>may hold promise for future therapy.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Discussion of Management</STRONG></FONT><P>

<I>Dr. Israel:</I> The main objective of management of this condition<SUP> </SUP>is the pursuit of an entirely gluten-free diet, eliminating<SUP> </SUP>all food products made from wheat, rye, and barley. Oats have<SUP> </SUP>traditionally also been prohibited, but studies in both adults<SUP> </SUP>and children<A HREF="#R40"><SUP>40</SUP></A> suggest that they may be consumed safely. The<SUP> </SUP>management of celiac disease in this patient began with a consultation<SUP> </SUP>with a nutritionist who is well versed in the gluten-free diet.<SUP> </SUP>It is much simpler to keep to a gluten-free diet now than it<SUP> </SUP>was even 10 years ago, since the number of commercially available<SUP> </SUP>products that are free of gluten has expanded and there is now<SUP> </SUP>an international symbol to identify a gluten-free food product.<SUP> </SUP>Support groups for patients with celiac disease have published<SUP> </SUP>lists of gluten-free products, which the parents in this case<SUP> </SUP>consulted. Food additives, medications, emulsifiers, and stabilizers<SUP> </SUP>are important hidden sources of gluten that need to be reviewed.<SUP> </SUP>If the patient had had diarrhea or bloating, we would have recommended<SUP> </SUP>a lactose-free diet, as well, for the first one to two months,<SUP> </SUP>since the damage to the villi may cause transient lactose intolerance.<SUP> </SUP><P>

The need for micronutrient replacement in patients with celiac<SUP> </SUP>disease should be assessed. Iron, folate, vitamin D, and vitamin<SUP> </SUP>K may need to be supplemented, especially in those who have<SUP> </SUP>clinical evidence of malabsorption. This patient had very mild<SUP> </SUP>anemia on presentation, but his serum iron studies and vitamin<SUP> </SUP>B<SUB>12</SUB> and folate levels were normal, so supplements were not prescribed.<SUP> </SUP>Associated conditions such as thyroiditis and diabetes should<SUP> </SUP>be ruled out in patients with this disease.<SUP> </SUP><P>

Finally, we recommended screening for anti&#150;tissue transglutaminase<SUP> </SUP>antibodies in the patient's first-degree relatives, since their<SUP> </SUP>risk of having celiac disease is about 10 percent.<A HREF="#R9"><SUP>9</SUP></A><SUP>,</SUP><A HREF="#R41"><SUP>41</SUP></A><SUP>,</SUP><A HREF="#R42"><SUP>42</SUP></A> Both<SUP> </SUP>parents have been tested, and the results were negative.<SUP> </SUP><P>

<STRONG>Complications of Celiac Disease</STRONG><P>

More than 70 percent of patients with clinical symptoms respond<SUP> </SUP>within two weeks of the initiation of the gluten-free diet.<SUP> </SUP>If the symptoms persist, the possibility of hidden sources of<SUP> </SUP>gluten in the diet should be considered. Testing for antigliadin<SUP> </SUP>antibody is very sensitive for the ingestion of gluten. Persistent<SUP> </SUP>diarrhea may be caused by coexisting lactose intolerance, irritable<SUP> </SUP>bowel syndrome, or pancreatic insufficiency. Refractory celiac<SUP> </SUP>disease may indicate the presence of lymphoma.<A HREF="#R43"><SUP>43</SUP></A> Enteropathy-type<SUP> </SUP>T-cell lymphoma, adenocarcinoma of the small bowel, and squamous-cell<SUP> </SUP>carcinoma of the esophagus are associated with celiac disease<A HREF="#R44"><SUP>44</SUP></A>;<SUP> </SUP>elimination of gluten from the diet appears to reduce the risk<SUP> </SUP>of death from some of these disorders.<A HREF="#R45"><SUP>45</SUP></A><SUP> </SUP><P>

<I>Dr. Levitsky:</I> This patient and his family were very conscientious<SUP> </SUP>in adhering to a gluten-free diet, although this was difficult<SUP> </SUP>for all of them. Within three months, he had gained 2.72 kg<SUP> </SUP>and grown about 1 cm taller; four months later he had grown<SUP> </SUP>another 4 cm and gained 3.76 kg. At his most recent visit, 17<SUP> </SUP>months after the diagnosis, he is in puberty; his height is<SUP> </SUP>174 cm and weight 56.8 kg (<A HREF="#F1">Figure 1</A>). The levels of IgA antiendomysial<SUP> </SUP>antibody fell from 1:1280 to 1:40 at 7 months, were undetectable<SUP> </SUP>at 12 months, but were again positive at 1:40 at 17 months on<SUP> </SUP>a gluten-free diet.<SUP> </SUP><P>

<I>Dr. Harris:</I> What is the current recommendation for screening<SUP> </SUP>populations for celiac disease?<SUP> </SUP><P>

<I>Dr. Israel:</I> The World Health Organization has established a<SUP> </SUP>set of principles to guide the development of screening programs.<A HREF="#R46"><SUP>46</SUP></A><SUP> </SUP>Celiac disease meets most of these criteria: it is a disorder<SUP> </SUP>that is difficult to diagnose clinically, failure to make an<SUP> </SUP>accurate diagnosis can have profound ramifications, there is<SUP> </SUP>an effective treatment for the condition, and there is a highly<SUP> </SUP>sensitive and specific means of detecting even clinically silent<SUP> </SUP>cases. What has not been determined, however, is whether the<SUP> </SUP>risk&#150;benefit ratio favors mass screening of asymptomatic<SUP> </SUP>patients. The current recommendations for the screening of asymptomatic<SUP> </SUP>persons include the testing of patients with conditions associated<SUP> </SUP>with celiac disease, such as type 1 diabetes, as well as first-degree<SUP> </SUP>relatives of patients who have celiac disease. Mass screening<SUP> </SUP>is not recommended at this point.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Anatomical Diagnosis</STRONG></FONT><P>

Celiac disease.<SUP> </SUP><P>

<SUP> </SUP><P>

<SUP> </SUP><P>


<FONT SIZE=-1></FONT>
<FONT SIZE=-1></FONT>
<BR><FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Source Information</STRONG></FONT><P><FONT SIZE=-1>
From the Department of Pediatrics, the Divisions of Pediatric Gastroenterology and Nutrition (E.J.I.) and Pediatric Endocrinology (L.L.L.) and the Departments of Radiology (S.A.A.) and Pathology (M.B.P.), Massachusetts General Hospital; and the Departments of Pediatrics (E.J.I., L.L.L.), Radiology (S.A.A.), and Pathology (M.B.P.), Harvard Medical School.
</FONT><P>


<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>References</STRONG></FONT><P>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1> Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford, Calif.: Stanford University Press, 1959:51, 103-5.<!-- HIGHWIRE ID="352:4:393:1" --><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2>  Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-179.<!-- HIGHWIRE ID="352:4:393:2" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=archdischild&resid=51/3/170" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Levitsky LL. Short stature. In: Dershewitz RA, ed. Ambulatory pediatric care. 3rd ed. Philadelphia: Lippincott-Raven, 1999:504-9.<!-- HIGHWIRE ID="352:4:393:3" --><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4>  Rossi TM, Albini CH, Kumar V. Incidence of celiac disease identified by the presence of serum endomysial antibodies in children with chronic diarrhea, short stature, or insulin-dependent diabetes mellitus. J Pediatr 1993;123:262-264.<!-- HIGHWIRE ID="352:4:393:4" --><A HREF="/cgi/external_ref?access_num=A1993LR29500014&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=8345423&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5>  van Rijn JC, Grote FK, Oostdijk W, Wit JM. Short stature and the probability of coeliac disease, in the absence of gastrointestinal symptoms. Arch Dis Child 2004;89:882-883.<!-- HIGHWIRE ID="352:4:393:5" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=archdischild&resid=89/9/882" ><nobr>[Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6>  Eichler I, Frisch H, Granditsch G. Growth failure and insulin-like growth factor (IGF-1) in childhood celiac disease. Klin Wochenschr 1991;69:825-829.<!-- HIGHWIRE ID="352:4:393:6" --><A HREF="/cgi/external_ref?access_num=A1991GP86300002&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=1770750&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7>  Forsberg G, Hernell O, Melgar S, Israelsson A, Hammarstrom S, Hammarstrom ML. Paradoxical coexpression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease. Gastroenterology 2002;123:667-678.<!-- HIGHWIRE ID="352:4:393:7" --><A HREF="/cgi/external_ref?access_num=10.1053/gast.2002.35355&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000177681700006&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=12198691&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8>  Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med 2002;346:180-188.<!-- HIGHWIRE ID="352:4:393:8" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=nejm&resid=346/3/180" ><nobr>[Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9>  Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003;163:286-292.<!-- HIGHWIRE ID="352:4:393:9" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=archinte&resid=163/3/286" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10>  Bottaro G, Cataldo F, Rotolo N, Spina M, Corazza GR. The clinical pattern of subclinical/silent celiac disease: an analysis of 1026 consecutive cases. Am J Gastroenterol 1999;94:691-696.<!-- HIGHWIRE ID="352:4:393:10" --><A HREF="/cgi/external_ref?access_num=10.1016/S0002-9270(98)00819-3&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000079134400029&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=10086653&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11>  Green PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 2001;96:126-131.<!-- HIGHWIRE ID="352:4:393:11" --><A HREF="/cgi/external_ref?access_num=10.1016/S0002-9270(00)02255-3&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000166435400022&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=11197241&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12>  Hoffman RJ, Dhaliwal G, Gilden DJ, Saint S. Special cure. N Engl J Med 2004;351:1997-2002.<!-- HIGHWIRE ID="352:4:393:12" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=nejm&resid=351/19/1997" ><nobr>[Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13>  Holmes GKT. Screening for coeliac disease in type 1 diabetes. Arch Dis Child 2002;87:495-498.<!-- HIGHWIRE ID="352:4:393:13" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=archdischild&resid=87/6/495" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14>  Collin P, Reunala T, Pukkala E, Laippala P, Keyrilainen O, Pasternack A. Coeliac disease -- associated disorders and survival. Gut 1994;35:1215-1218.<!-- HIGHWIRE ID="352:4:393:14" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=gutjnl&resid=35/9/1215" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15>  Ventura A, Magazzu G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. Gastroenterology 1999;117:297-303.<!-- HIGHWIRE ID="352:4:393:15" --><A HREF="/cgi/external_ref?access_num=000081673400006&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=10419909&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16>  Leonard JN, Chorzelski TP, Beutner EH, et al. IgA anti-endomysial antibody detection in the serum of patients with dermatitis herpetiformis following gluten challenge. Arch Dermatol Res 1985;277:349-351.<!-- HIGHWIRE ID="352:4:393:16" --><A HREF="/cgi/external_ref?access_num=10.1007/BF00509231&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=A1985ALE1900002&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=4026376&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R17"><!-- null --></A>
<LI VALUE=17>  Dietrich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801.<!-- HIGHWIRE ID="352:4:393:17" --><A HREF="/cgi/external_ref?access_num=A1997XG76700044&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=9212111&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R18"><!-- null --></A>
<LI VALUE=18>  Meeuwisse GW. Roundtable discussion: diagnostic criteria in celiac disease. Acta Paediatr Scand 1970;59:461-463.<!-- HIGHWIRE ID="352:4:393:18" --><!-- /HIGHWIRE --><A NAME="R19"><!-- null --></A>
<LI VALUE=19>  Walker-Smith JA, Guandalini S, Shmerling DH, Visakorpi JK. Revised criteria for diagnosis of celiac disease: report of the Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990;65:909-911.<!-- HIGHWIRE ID="352:4:393:19" --><A HREF="/cgi/external_ref?access_num=A1990DR15200029&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=2205160&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R20"><!-- null --></A>
<LI VALUE=20> Fenoglio-Preiser CM. Non-neoplastic lesions of the small intestine. In: Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Listrom MB, Rilke FO, eds. Gastrointestinal pathology: an atlas and text. 2nd ed. Philadelphia: Lippincott-Raven, 1999:309-458.<!-- HIGHWIRE ID="352:4:393:20" --><!-- /HIGHWIRE --><A NAME="R21"><!-- null --></A>
<LI VALUE=21>  Marsh MN. Gluten, major histocompatibility complex, and the small intestine: a molecular and immunobiologic approach to the spectrum of gluten sensitivity ("celiac sprue"). Gastroenterology 1992;102:330-354.<!-- HIGHWIRE ID="352:4:393:21" --><A HREF="/cgi/external_ref?access_num=A1992GX35500045&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=1727768&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R22"><!-- null --></A>
<LI VALUE=22>  Russell GJ, Winter HS, Fox VL, Bhan AK. Lymphocytes bearing the <IMG SRC="/math/ggr.gif" ALT="{gamma}" BORDER="0"><IMG SRC="/math/dgr.gif" ALT="{delta}" BORDER="0"> T-cell receptor in normal human intestine and celiac disease. Hum Pathol 1991;22:690-694.<!-- HIGHWIRE ID="352:4:393:22" --><A HREF="/cgi/external_ref?access_num=10.1016/0046-8177(91)90291-V&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=A1991GQ80100010&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=1906424&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R23"><!-- null --></A>
<LI VALUE=23>  Goldstein NS, Underhill J. Morphologic features of gluten sensitivity in architecturally normal duodenal biopsy specimens. Am J Clin Pathol 2001;116:63-71.<!-- HIGHWIRE ID="352:4:393:23" --><A HREF="/cgi/external_ref?access_num=10.1309/5PRJ-CM0U-6KLD-6KCM&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000169531900009&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=11447753&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R24"><!-- null --></A>
<LI VALUE=24>  Jarvinen TT, Kaukinen K, Laurila K, et al. Intraepithelial lymphocytes in celiac disease. Am J Gastroenterol 2003;98:1332-1337.<!-- HIGHWIRE ID="352:4:393:24" --><A HREF="/cgi/external_ref?access_num=10.1016/S0002-9270(03)00230-2&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000183615400019&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=12818278&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R25"><!-- null --></A>
<LI VALUE=25>  Mino M, Lauwers GY. Role of lymphocytic immumophenotyping in the diagnosis of gluten-sensitive enteropathy with preserved villous architecture. Am J Surg Pathol 2003;27:1237-1242.<!-- HIGHWIRE ID="352:4:393:25" --><A HREF="/cgi/external_ref?access_num=000185005800007&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=12960808&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R26"><!-- null --></A>
<LI VALUE=26>  Greenberg DA, Lange KL. A maximum likelihood test of the two locus model for celiac disease. Am J Med Genet 1982;12:75-82.<!-- HIGHWIRE ID="352:4:393:26" --><A HREF="/cgi/external_ref?access_num=A1982NN79600009&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=7091198&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R27"><!-- null --></A>
<LI VALUE=27>  Sollid LM. Molecular basis of celiac disease. Annu Rev Immunol 2000;18:53-81.<!-- HIGHWIRE ID="352:4:393:27" --><A HREF="/cgi/external_ref?access_num=10.1146/annurev.immunol.18.1.53&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000087236500003&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=10837052&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R28"><!-- null --></A>
<LI VALUE=28>  Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology 2000;119:234-242.<!-- HIGHWIRE ID="352:4:393:28" --><A HREF="/cgi/external_ref?access_num=000088108800031&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=10889174&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R29"><!-- null --></A>
<LI VALUE=29>  Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac disease. Science 2002;297:2275-2279.<!-- HIGHWIRE ID="352:4:393:29" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=sci&resid=297/5590/2275" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R30"><!-- null --></A>
<LI VALUE=30>  Qiao S-W, Bergseng E, Molberg O, et al. Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol 2004;173:1757-1762.<!-- HIGHWIRE ID="352:4:393:30" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jimmunol&resid=173/3/1757" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R31"><!-- null --></A>
<LI VALUE=31>  Howell MD, Austin RK, Kelleher D, Nepom GT, Kagnoff MF. An HLA-D region restriction fragment length polymorphism associated with celiac disease. J Exp Med 1986;164:333-338.<!-- HIGHWIRE ID="352:4:393:31" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jem&resid=164/1/333" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R32"><!-- null --></A>
<LI VALUE=32>  Lundin KE, Scott H, Fausa O, Thorsby E, Sollid LM. T cells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Hum Immunol 1994;41:285-291.<!-- HIGHWIRE ID="352:4:393:32" --><A HREF="/cgi/external_ref?access_num=10.1016/0198-8859(94)90047-7&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=A1994PY18800006&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=7883596&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R33"><!-- null --></A>
<LI VALUE=33>  Brandtzaeg P, Halstensen TS, Kett K, et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 1989;97:1562-1584.<!-- HIGHWIRE ID="352:4:393:33" --><A HREF="/cgi/external_ref?access_num=A1989CB94100029&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=2684725&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R34"><!-- null --></A>
<LI VALUE=34>  Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT. A major role of matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-1590.<!-- HIGHWIRE ID="352:4:393:34" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jimmunol&resid=158/4/1582" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R35"><!-- null --></A>
<LI VALUE=35>  Matysiak-Budnik T, Candalh C, Dugave C, et al. Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology 2003;125:696-707.<!-- HIGHWIRE ID="352:4:393:35" --><A HREF="/cgi/external_ref?access_num=10.1016/S0016-5085(03)01049-7&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000185172300011&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=12949716&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R36"><!-- null --></A>
<LI VALUE=36>  Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 2000;113:4435-4440.<!-- HIGHWIRE ID="352:4:393:36" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=joces&resid=113/24/4435" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R37"><!-- null --></A>
<LI VALUE=37>  Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003;52:218-223.<!-- HIGHWIRE ID="352:4:393:37" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=gutjnl&resid=52/2/218" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R38"><!-- null --></A>
<LI VALUE=38>  Fasano A, Not T, Wang W, et al. A newly discovered modulator of intestinal permeability, and its expression in celiac disease. Lancet 2000;355:1518-1519.<!-- HIGHWIRE ID="352:4:393:38" --><A HREF="/cgi/external_ref?access_num=10.1016/S0140-6736(00)02169-3&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000086830100016&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=10801176&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R39"><!-- null --></A>
<LI VALUE=39>  Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002;283:G996-G1003.<!-- HIGHWIRE ID="352:4:393:39" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajpgi&resid=283/4/G996" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R40"><!-- null --></A>
<LI VALUE=40>  Hoffenberg E, Haas J, Drescher A, et al. A trial of oats in children with newly diagnosed celiac disease. J Pediatr 2000;137:361-366.<!-- HIGHWIRE ID="352:4:393:40" --><A HREF="/cgi/external_ref?access_num=10.1067/mpd.2000.109003&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000089305700014&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=10969261&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R41"><!-- null --></A>
<LI VALUE=41>  Farre C, Humbert P, Vilar P, et al. Serological markers and HLA-DQ2 haplotype among first-degree relatives of celiac patients. Dig Dis Sci 1999;44:2344-2349.<!-- HIGHWIRE ID="352:4:393:41" --><A HREF="/cgi/external_ref?access_num=000083683100029&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=10573385&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R42"><!-- null --></A>
<LI VALUE=42>  Book L, Zone JJ, Neuhausen SL. Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. Am J Gastroenterol 2003;98:377-381.<!-- HIGHWIRE ID="352:4:393:42" --><A HREF="/cgi/external_ref?access_num=10.1016/S0002-9270(02)05906-3&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000180992700031&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=12591058&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R43"><!-- null --></A>
<LI VALUE=43>  Carbonnel F, Grollet-Bioul L, Brouet JC, et al. Are complicated forms of celiac disease cryptic T-cell lymphomas? Blood 1998;92:3879-3886.<!-- HIGHWIRE ID="352:4:393:43" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=bloodjournal&resid=92/10/3879" ><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R44"><!-- null --></A>
<LI VALUE=44>  Pricolo VE, Mangi AA, Aswad B, Bland KI. Gastrointestinal malignancies in patients with celiac sprue. Am J Surg 1998;176:344-347.<!-- HIGHWIRE ID="352:4:393:44" --><A HREF="/cgi/external_ref?access_num=10.1016/S0002-9610(98)00193-7&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000076785500013&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=9817252&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R45"><!-- null --></A>
<LI VALUE=45>  Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease -- effect of a gluten free diet. Gut 1989;30:333-338.<!-- HIGHWIRE ID="352:4:393:45" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=gutjnl&resid=30/3/333" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R46"><!-- null --></A>
<LI VALUE=46> Wilson JM. Principles and practice of screening for diseases. Geneva: World Health Organization, 1968.<!-- HIGHWIRE ID="352:4:393:46" --><!-- /HIGHWIRE --></OL>






		
        
        
	
	
	
	
	






 




<BR CLEAR=ALL>


	
	 
		  
			 
			
			                    



 
	 

<table border="0" cellpadding="0" cellspacing="0" width="200" ALIGN="RIGHT">
<tr>
<td width="20">&nbsp;</td>
<TD BGCOLOR="336699">

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="1">

	<TR VALIGN="top">
		<td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
			<img src="/icons/v3_this_article.gif" alt="This Article" width="73" height="8" BORDER="0"><BR>
			<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
	</tr><tr>
		<td> 
                <table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
		<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
		
		
		
		

		
		 

		
		<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b>
			
			
			
				
						
						<A class="contentboxLinks" HREF="/cgi/reprint/352/4/393.pdf">PDF</A></b></font></td></tr>
		
		<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/ac_external_ref?link_type=pda_mms&doi=10.1056%2FNEJMcpc049032">PDA Full Text</A></b></font></td></tr>
		
		
		

		

		

		 
		
		



	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	</table>
        </td>
        </tr>









	<tr> 
	<td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
	<img src="/icons/v3_tools_service.gif" alt="Tools and Services" width="103" height="9" align="absmiddle"><BR>
	<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
	</tr>
	<tr> 
	<td> 
	<table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	
		
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/folders?action=addtofolder&wherefrom=JOURNALS&wrapped_id=nejm;352/4/393">Add to Personal Archive</A></b></font></td></tr>
	
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/citmgr?gca=nejm;352/4/393">Add to Citation Manager</A></b></font></td></tr>
	
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/mailafriend?url=http://content.nejm.org/cgi/content/short/352/4/393&title=Case+3-2005+-+A+14-Year-Old+Boy+with+Recent+Slowing+of+Growth+and+Delayed+Puberty"><b>Notify a Friend</b></a></b></font></td></tr>

	
        <tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=nejm;352/4/393&return_type=article&return_url=%2Fcgi%2Fcontent%2Ffull%2F352%2F4%2F393">E-mail When Cited</A></b></font></td></tr>

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/ac_external_ref?link_type=letters_mms&doi=10.1056%2FNEJMcpc049032">E-mail When Letters Appear</A></b></font></td></tr>
	
	
	
	

	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	</table>
        </td>
        </tr>



        <tr>
        <td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
	<img src="/icons/v3_more_information.gif" alt="More Information" width="116" height="8" align="absmiddle"><BR>
	<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
        </tr>
        <tr>
        <td>
        <table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
        

	

	

	

	

	

	

	

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/search?qbe=nejm;352/4/393&journalcode=nejm&minscore=5000">Find Similar Articles</A></b></font></td></tr>

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/external_ref?access_num=15673806&link_type=PUBMED" onClick="ISIwin('ISI')" TARGET="ISI">PubMed Citation</A></b></font></td></tr>

<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
</table>
</td>
</tr>

        
        
</table>
</table>	 <!-- end of outer content box1 -->
</TABLE>	 <!-- end of outer content box2 -->



			
			
					
	









<BR CLEAR=ALL>


	

	<table width="100%" border="0" cellspacing="0" cellpadding="0" align="center">
	<tr> 
	<td align="center"><hr size="1" color="#000000" noshade>
	<p><font face="arial, helvetica, sans-serif">
	<a href="/" class="footerLinks">HOME</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/search.dtl" class="footerLinks">SEARCH</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/current.shtml" class="footerLinks">CURRENT ISSUE</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/contents-by-date.0.shtml" class="footerLinks">PAST ISSUES</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/collections/" class="footerLinks">COLLECTIONS</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/help/" class="footerLinks">HELP</a>
</font></p>
	<p><font face="arial, helvetica, sans-serif">Comments and questions?
	Please <a href="http://www.nejm.org/custserv/feedback.asp">contact us</a>.</font></p>
	<p><font face="Times New Roman">
	<font face="Times New Roman"><b>The New England Journal of Medicine is owned, published, and <a href="http://www.nejm.org/aboutnejm/copyright.asp">copyrighted</a> &copy; 2005 <A HREF ="http://www.massmed.org/">Massachusetts Medical Society</A>.
	All rights reserved.</b></font>
</font></p></td>
	</tr>
	</table>



        <SCRIPT LANGUAGE="JavaScript">
        <!--
        function startTarget(windowname,wid,hei) {
        
        var dotpos = windowname.indexOf(".");
        if (dotpos > -1)
        {
        var tempwn = windowname.substring(0,dotpos) +
                windowname.substring(dotpos + 1, windowname.length);
        windowname = tempwn;
        }
        var sizestring = 'width=' + wid + ',height=' + hei;
        window.open('',windowname,'scrollbars,resizable,menubar,' + sizestring + '\'');
        }
        // -->
        </SCRIPT>

<script language="JavaScript">
<!--
if ( top != self )
{
     top.location.href = unescape(window.location.pathname);
}

function ISIwin(windowname) {
	var dotpos = windowname.indexOf(".");
	if (dotpos > -1) {
		var tempwn = windowname.substring(0,dotpos) +
        windowname.substring(dotpos + 1, windowname.length);
		windowname = tempwn;
	}
	newwin = window.open('', windowname, 'width=700,height=400,left=30,top=30,screenX=30,screenY=30,resizable,scrollbars,toolbar,location,status,menubar');
	setTimeout('newwin.focus();',250);
}

//-->
</script>

</BODY>
</HTML>

